TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28167156
Drug: Eluxadoline 75
Normalized name: eluxadoline 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eluxadoline 75 mg
Study: 15337695
Drug: Nesiritide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesiritide (2 microg/kg IV bolus followed by an infusion of 0.01 microg/kg per minute)
Study: 9257066
Drug: Different radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different radiation doses
Study: 8329252
Drug: Nasal administration
Normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal administration of midazolam 0.2 mg kg‐1
Study: 8329252
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of midazolam 0.2 mg kg‐1
Study: 8329252
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of midazolam 0.2 mg kg‐1
Study: 3518624
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (2.1 g/day on a twice‐daily regimen)
Study: 3518624
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (1.05 g/day on a twice‐daily regimen)
Study: 3518624
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (active medication)
Study: 27655538
Drug: Zinc supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplement (zinc gluconate granules for 10 days)
Study: 20604703
Drug: Extended cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended cognitive behavior therapy for cigarette smoking cessation
Study: 20604703
Drug: Model 1
Normalized name: Model AA 2012 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model 1 (pretreatment factors, demographic characteristics, treatment assignment)
Study: 20604703
Drug: Model 2
Normalized name: Model 2004FAA Model 3-EEMK Model 3-EEMK-1 Model AA-8565 Model AA-8565-LATAM Model AWFAREMK Model CHAUTAUQUAEMK Model emk1000-10 Model FAREMK Model PMONTFAREMK Model SWEEMK Model SWEEMK-1 Model QXEMK Model G4FAREMK Model AA-8565 (excluding Miami Air) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model 2 (Model 1 variables + clinical data during treatment)
Study: 9691858
Drug: midazolam 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.03 mg kg‐1 i.v.
Study: 9691858
Drug: midazolam 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: midazolam 0.06 mg kg‐1 i.v.
Study: 25385878
Drug: Nicotine inhaler
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhaler device (0.22 mg, 0.45 mg, 0.67 mg doses)
Study: 25385878
Drug: Nicotine inhaler
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine inhaler device (0.67 mg repeated hourly for 12 hr)
Study: 19487269
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 or 100 mg every 2 or 4 weeks + MTX
Study: 14769595
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brimonidine and dorzolamide
Study: 3907843
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg OD
Study: 3907843
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg OD
Study: 30001703
Drug: Positive STEPS
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Positive STEPS intervention (two-way daily text messaging as a reminder system, progressing to in-person counseling if needed)
Study: 28956786
Drug: Liraglutide added
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide added to insulin for 26 weeks
Study: 28956786
Drug: Liraglutide added
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide added to insulin for 8 weeks
Study: 24490058
Drug: Glucomannan (1.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan (1.33 grams taken with 236.6 mL of water before meals)
Study: 24490058
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically looking capsules taken with 236.6 mL of water before meals)
Study: 21996369
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methotrexate (HDM), n = 79
Study: 11059442
Drug: Antidepressant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant therapy (including tricyclic antidepressants such as amitriptyline, clomipramine, desipramine, doxepin, trimipramine, and the antiserotonin agent mianserin)
Study: 23471307
Drug: Prophylactic G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic G-CSF
Study: 1736695
Drug: Intravenous diclofenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diclofenac 75 mg loading dose followed by 5 mg/hour infusion
Study: 3963154
Drug: Morphine and
Normalized name: morphine and antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine and glycopyrrolate
Study: 31542446
Drug: Customized Consumer
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Customized Consumer Medication Information (C-CMI)
Study: 23948349
Drug: Dose-dense treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense treatment (carboplatin AUC 6 mg/mL per min on day 1 and paclitaxel 80 mg/m2 on days 1, 8, and 15)
Study: 23948349
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (carboplatin AUC 6 mg/mL per min and paclitaxel 180 mg/m2 on day 1)
Study: 20104529
Drug: Control (azulene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (azulene oral rinse)
Study: 16807754
Drug: Dyed test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyed test formulation administered intranasally
Study: 16807754
Drug: Lateral head
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral head position during administration
Study: 14682142
Drug: Accelerated hyperfractionation
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated hyperfractionation (AHF) 1.3 Gy, twice a day, 5 weeks, total 57.2-70 Gy
Study: 8615463
Drug: thigh-high, vinyl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: thigh-high, vinyl, sequential-pulse IPC system
Study: 1535419
Drug: Aspirin before
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin before myocardial infarction
Study: 1535419
Drug: Aspirin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin after myocardial infarction
Study: 1535419
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists after myocardial infarction
Study: 27684533
Drug: weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: weekly paclitaxel
Study: 20663996
Drug: Argatroban (250,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (250, 300, or 350 µg/kg as bolus before PCI, followed by 15, 20, or 25 µg/kg/min infusion)
Study: 20663996
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (70-100 IU/kg bolus)
Study: 11868762
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg tablets b.i.d. for 7 d
Study: 11868762
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid 1000 mg tablets o.d. for 7 d
Study: 12515162
Drug: L-HSA-Ara-AMP (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-HSA-Ara-AMP (35 mg/Kg daily for 5 days)
Study: 7989928
Drug: Preparatory regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparatory regimen consisting of fractionated total-body irradiation (12 Gy total administered in 10 1.2-Gy fractions), etoposide (60 mg/kg), and cyclophosphamide (100 mg/kg).
Study: 2543553
Drug: Beet-fibre diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beet-fibre diet (mean 40 g FibrexR, 27 g dietary fibre per day)
Study: 1123455
Drug: Betahistine hydrochloride
Normalized name: Betahistine Hydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine hydrochloride (SERC), 20 mg
Study: 1123455
Drug: Betahistine hydrochloride
Normalized name: Betahistine Hydrochloride
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine hydrochloride (SERC), high dosage (16 mg)
Study: 26403410
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (methylprednisolone aceponat), applied once a day for three months (group A)
Study: 26403410
Drug: Topical calcineurin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcineurin inhibitors (tacrolimus), applied twice a day for three months (group B)
Study: 23948642
Drug: Risk score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk score based on clinical variables (age, residence, body mass index, on-treatment heart rate and BP, prior myocardial infarction, heart failure, stroke/transient ischemic attack, smoking, diabetes, peripheral arterial disease, chronic kidney disease)
Study: 21480317
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon and ribavirin therapy
Study: 16918513
Drug: VLA-4 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: VLA-4 antagonist GW559090X (3 mg)
Study: 15307010
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg once-daily lamivudine (3TC)
Study: 15307010
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg twice-daily lamivudine (3TC)
Study: 15307010
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg twice-daily zidovudine
Study: 15307010
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg once-daily efavirenz
Study: 11795863
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication therapy (triple-therapy: Clarithromycin, Amoxicillin, and Omeprazole for one week)
Study: 9463301
Drug: New allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: New allopurinol formulation (300 mg)
Study: 9463301
Drug: Reference allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference allopurinol formulation
Study: 8431665
Drug: Enalapril (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (0.1 mg/kg)
Study: 26850803
Drug: Lavender essential
Normalized name: Nature's Truth Lavender Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender essential oil inhalation (5% for 10 min, three times a week for 4 weeks)
Study: 24225740
Drug: Antioxidant capsule
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant capsule group (AO group)
Study: 16793163
Drug: Information booklet
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information booklet (the 'back book') and usual physical therapy
Study: 16793163
Drug: Usual physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual physical therapy only with nonstandardized oral information
Study: 14738126
Drug: Lozenge containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge containing 56.4mg (3 percent w/w) CPP-ACP
Study: 14738126
Drug: Lozenge containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge containing 18.8mg (1 percent w/w) CPP-ACP
Study: 14738126
Drug: Lozenge not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge not containing CPP-ACP
Study: 14738126
Drug: No lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lozenge nil-treatment control
Study: 2850904
Drug: enalapril 10-20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10-20 mg/d
Study: 2850904
Drug: hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide (HCTZ) 12.5-25 mg/d
Study: 2850904
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy (enalapril + HCTZ)
Study: 27661661
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow MSCs by intradiscal injection of 25 × 10 cells per segment under local anesthesia
Study: 23289530
Drug: KPS improvement
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: KPS improvement during therapy
Study: 18057912
Drug: Clo‐Met (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clo‐Met (100 mg clotrimazole and 100 mg metronidazole)
Study: 16931507
Drug: Pramipexole 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.50 mg/day
Study: 9214527
Drug: Pramipexole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole (all doses combined)
Study: 12656937
Drug: Daily left
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily left prefrontal rTMS (5 Hz, 110% motor threshold, 8 sec on, 22 sec off, over 20 min) for 2 weeks
Study: 12656937
Drug: Daily left
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily left prefrontal rTMS
Study: 380367
Drug: Haloperidol 20-35
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 20-35 mg intravenously
Study: 380367
Drug: Diazepam 30-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 30-40 mg intravenously
Study: 29029049
Drug: High-remifentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-remifentanil with naloxone (4 ng ml-1 remifentanil with 0.05 μg kg-1 h-1 naloxone)
Study: 29029049
Drug: High-remifentanil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-remifentanil (4 ng ml-1 remifentanil)
Study: 29029049
Drug: Low-remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-remifentanil (1 ng ml-1 remifentanil)
Study: 26371617
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) plus treatment-as-usual (TAU)
Study: 26371617
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral analysis system of psychotherapy (CBASP) plus treatment-as-usual (TAU)
Study: 21210958
Drug: Intimacy-Enhancing Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intimacy-Enhancing Therapy (IET)
Study: 16760445
Drug: Ciprofloxacin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (1 g single dose)
Study: 14757848
Drug: BQ-123 (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQ-123 (32 microg/min for 120 min) during placebo or insulin clamp
Study: 11211371
Drug: Fluvoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 50 to 200 mg/day
Study: 2656623
Drug: Cefmetazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole (2 g intra-operative iv dose)
Study: 2656623
Drug: Cefotetan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotetan (2 g intra-operative iv dose)
Study: 4943034
Drug: Penfluridol 30
Normalized name: penfluridol
DrugBank: Penfluridol (DB13791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol 30 mg weekly oral dose
Study: 23690582
Drug: B-vitamin treatment
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin treatment (folic acid 0.8 mg, vitamin B6 20 mg, vitamin B12 0.5 mg)
Study: 23690582
Drug: B-vitamin treatment
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B-vitamin treatment
Study: 21486960
Drug: TBR-652 (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBR-652 (25, 50, 75, 100, and 150 mg)
Study: 16977280
Drug: Gardasil (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil (recombinant quadrivalent human‐papillomavirus‐like particle vaccine)
Study: 30464407
Drug: Fasted condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasted condition (entecavir administration)
Study: 30464407
Drug: Fed condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed condition (entecavir administration)
Study: 20231857
Drug: Nicotine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (4 mg as gum)
Study: 11157665
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide synthesis inhibitor N:(G)monomethyl‐L‐arginine (5.3+/‐1.2%)
Study: 11157665
Drug: Prolonged episodes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prolonged episodes of reactive hyperemia, hand warming, or incremental infusion of acetylcholine
Study: 9128028
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine 150 micrograms 60-90 min prior to arrival in the operating room
Study: 3295020
Drug: Lactitol (66.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (66.7 g/100 ml)
Study: 3295020
Drug: Lactulose (66.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (66.7 ml (44.5 g)/100 ml)
Study: 31351085
Drug: BoNT &
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT & occupational therapy
Study: 31351085
Drug: BoNT therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT therapy alone
Study: 25793765
Drug: Insulin regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin regimen
Study: 21872452
Drug: Catecholamine depletion
Normalized name: Allogeneic thymocyte-depleted thymus tissue-agdc
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catecholamine depletion (CD) using oral alpha‐methyl‐para‐tyrosine
Study: 19141997
Drug: Paricalcitol treatment
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol treatment under DCa = 3.5 mEq/l
Study: 19141997
Drug: Paricalcitol treatment
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol treatment under DCa = 3.0 mEq/l
Study: 19141997
Drug: Paricalcitol treatment
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol treatment under DCa = 2.5 mEq/l
Study: 11372675
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) (13.0 kDa)
Study: 11372675
Drug: Medium molecular
Normalized name: chitosan medium molecular weight (200-800 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium molecular weight heparin (HF) (10.5 kDa)
Study: 8159637
Drug: 12 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 IU/ml preparation of growth hormone
Study: 8159637
Drug: 56 IU/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56 IU/ml preparation of growth hormone
Study: 31193613
Drug: Standard prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylactic intravenous hydration
Study: 26683546
Drug: Emphasis terms
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emphasis terms in warning directives (e.g., 'urgent', 'recommended')
Study: 26683546
Drug: Emphasis terms
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emphasis terms in warning directives (e.g., 'important', 'compulsory')
Study: 19317164
Drug: Dannang Recipe
Normalized name: SALICYLIC ACID 1 g in 100 mL TOPICAL SHAMPOO [Maetria Miracle Recipe PremiumShampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dannang Recipe No. 2 (DNR2) - one dose per day starting from the previous night of operation, composed of various herbal ingredients.
Study: 19317164
Drug: Ceftizoxime sodium
Normalized name: Ceftizoxime Sodium
DrugBank: Ceftizoxime (DB01332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftizoxime sodium 2.0 g or Levofloxacin 200 mg via intravenous dripping once 0.5 h before operation and 1-3 days after operation.
Study: 11707687
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg and Enalapril 10 mg
Study: 11707687
Drug: Nitrendipine 5
Normalized name: nitrendipine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 5 mg
Study: 11707687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nitrendipine and enalapril
Study: 7963143
Drug: Beta-carotene administration
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene administration without a meal
Study: 7963143
Drug: Beta-carotene administration
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene administration with meals (varied calories and fat)
Study: 7963143
Drug: Beta-carotene administration
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene administration with high dietary fat